Compare NTST & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | BCRX |
|---|---|---|
| Founded | 2019 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 2020 | 1994 |
| Metric | NTST | BCRX |
|---|---|---|
| Price | $20.16 | $6.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $20.27 | ★ $20.82 |
| AVG Volume (30 Days) | 1.7M | ★ 4.3M |
| Earning Date | 02-10-2026 | 02-26-2026 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | $195,006,000.00 | ★ $599,816,000.00 |
| Revenue This Year | $20.93 | $40.21 |
| Revenue Next Year | $10.80 | $6.13 |
| P/E Ratio | $245.16 | ★ N/A |
| Revenue Growth | 19.79 | ★ 45.38 |
| 52 Week Low | $13.74 | $6.00 |
| 52 Week High | $20.25 | $11.31 |
| Indicator | NTST | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 72.52 | 49.16 |
| Support Level | $18.70 | $6.26 |
| Resistance Level | $19.64 | $6.91 |
| Average True Range (ATR) | 0.48 | 0.27 |
| MACD | 0.11 | 0.05 |
| Stochastic Oscillator | 97.94 | 74.65 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.